10.1016/j.drudis.2017.04.015 164 WongrakpanichS.WongrakpanichA.MelhadoK.RangaswamiJ
Trends & Treatment Insights for 2025 Real-world data show rapid adoption in type 2 diabetes care: between early 2022 and mid-2024, roughly 1 in 5 type 2 diabetes patients were on GLP-1 therapy
In hyperthyroidism, elevated thyroid hormones suppress TSH, creating a dysregulated metabolic state
L-carnitine may support weight loss in many people
GLP-1s by year and indication GLP-1s by indication and year GLP-1 pipeline FAQs On Jan
When to contact your GP, diabetes team, or healthcare professional: Severe or persistent nausea and vomiting preventing adequate fluid or food intake Signs of dehydration (dark urine, dizziness, reduced urination) Severe abdominal pain, particularly if accompanied by vomiting, or right upper abdominal pain with fever Symptoms of hypoglycaemia that don't resolve with usual treatment Unexplained weight loss exceeding clinical targets Changes in mood or suicidal thoughts Any concerns about medication tolerance or effectiveness The MHRA continues to monitor the safety profile of incretin medications through the Yellow Card scheme
